Shanghai HeartCare Medical Technology Corporation Limited (06609.HK)

Shanghai Heartcare Medical Technology Corp. Ltd. engages in the research, development, manufacture, and sale of neuro-interventional medical devices. The company is headquartered in Shanghai, Shanghai and currently employs 327 full-time employees. The company went IPO on 2021-08-20. The Company’s key neuro-interventional products and product candidates include ischemic stroke thrombectomy devices such as Captor thrombectomy stent and aspiration catheter, intracranial stenosis treatment devices such as intracranial balloon dilatation catheter and carotid artery balloon dilatation catheter and embolization protection system, hemorrhagic stroke treatment devices such as vascular reconstruction device and flow diverter device, ischemic stroke prevention devices such as LAA occluder, and vascular access devices such as distal access catheter, microcatheter, balloon guiding catheter, and other devices. The firm mainly conducts its businesses within domestic market.